Innovative retatrutide, a dual -action treatment targeting both GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Early clinical trials have revealed significant decreases in body weight and gains in physiological markers for individuals with overweight. Researchers believe this ground-breaking approach has th